Tiziana Life Sciences LtdNASDAQ:TLSA
- LAST PRICE1.0100
- TODAY'S CHANGE (%)-0.0300 (-2.8846%)
- Bid / Lots0.9999/ 5
- Ask / Lots1.0300/ 382
- Open / Previous Close1.0300 / 1.0400
- Day Range
- 52 Week Range
- Volume139,157
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 3854 | 1.03 |
| 09:34 ET | 2501 | 1.025 |
| 09:36 ET | 15700 | 0.98 |
| 09:38 ET | 1240 | 1 |
| 09:43 ET | 1386 | 0.985 |
| 09:45 ET | 149 | 1 |
| 09:54 ET | 640 | 0.9925 |
| 09:56 ET | 295 | 0.985 |
| 09:57 ET | 6000 | 1 |
| 10:06 ET | 200 | 0.9925 |
| 10:08 ET | 200 | 1 |
| 10:15 ET | 100 | 0.9851 |
| 10:19 ET | 1000 | 0.988825 |
| 10:26 ET | 14989 | 0.99 |
| 10:28 ET | 500 | 1 |
| 10:30 ET | 200 | 1 |
| 10:32 ET | 1200 | 0.9999 |
| 10:35 ET | 5807 | 1 |
| 10:37 ET | 115 | 0.99995 |
| 10:39 ET | 3050 | 1.0199 |
| 10:50 ET | 5000 | 1.03 |
| 10:55 ET | 100 | 1.0114 |
| 11:04 ET | 11000 | 1.02 |
| 11:09 ET | 10000 | 1.02 |
| 11:11 ET | 1300 | 1.0199 |
| 11:24 ET | 100 | 1.01 |
| 11:26 ET | 100 | 1.015 |
| 11:27 ET | 380 | 1.0113 |
| 11:33 ET | 1000 | 1.015 |
| 11:40 ET | 108 | 1.02 |
| 11:47 ET | 960 | 1.0101 |
| 12:00 ET | 100 | 1.02 |
| 12:14 ET | 100 | 1.0187 |
| 12:21 ET | 400 | 1.01 |
| 12:32 ET | 4036 | 1.0194 |
| 12:36 ET | 1100 | 1.015 |
| 12:41 ET | 100 | 1.01 |
| 12:43 ET | 100 | 1.0101 |
| 12:45 ET | 500 | 1.0109 |
| 12:48 ET | 100 | 1.0187 |
| 12:57 ET | 100 | 1.015 |
| 01:03 ET | 1500 | 1.0108 |
| 01:10 ET | 480 | 1.011 |
| 01:21 ET | 2692 | 1.01 |
| 01:26 ET | 400 | 1.015 |
| 01:30 ET | 100 | 1.01 |
| 01:33 ET | 200 | 1.01 |
| 01:35 ET | 348 | 1.01 |
| 01:37 ET | 250 | 1.015 |
| 02:22 ET | 150 | 1.015 |
| 02:38 ET | 1000 | 1.015 |
| 02:51 ET | 106 | 1.016 |
| 03:02 ET | 134 | 1.0111 |
| 03:07 ET | 2264 | 1.015 |
| 03:14 ET | 1000 | 1.0107 |
| 03:18 ET | 3000 | 1.0105 |
| 03:23 ET | 600 | 1.0171 |
| 03:25 ET | 100 | 1.015 |
| 03:27 ET | 2025 | 1.0125 |
| 03:36 ET | 525 | 1.017023 |
| 03:38 ET | 2712 | 1.01 |
| 03:41 ET | 18015 | 1.02 |
| 03:48 ET | 700 | 1.0118 |
| 03:54 ET | 130 | 1.0108 |
| 03:59 ET | 521 | 1.01 |
Sep 19, 2024
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer's Disease, from 7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 107.2M | -5.9x | --- |
Annovis Bio Inc | 107.6M | -1.8x | --- |
Verastem Inc | 105.0M | -0.8x | --- |
Fibrobiologics Inc | 110.4M | -3.4x | --- |
INmune Bio Inc | 110.0M | -2.5x | --- |
X4 Pharmaceuticals Inc | 111.2M | 7.6x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer
- Ivor Elrifi
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $107.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.17 |
Book Value | $0.05 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
